Since HCK also interacts with the BCR/ABL fusion protein, this may have clinical relevance, whereby Imatinib can no longer bind to and inhibit the BCR/ABL fusion protein in CML patients [55, 122]. This evidence concerns the gene HCK and chronic myelogenous leukemia, BCR-ABL1 positive.